Skin Baseline

People with many moles, a melanoma history or fair skin pay out of pocket for reassurance between dermatologist visits, and the market already charges them: SkinVision sells one check for EUR 6.99 and unlimited checks for EUR 24.99 over three months or EUR 49.99 over a year, while Miiskin charges $2.99 for three months, $5.99 monthly or $29.99 yearly. Two things make this hard. First, the valuable part is regulated: SkinVision is an MDR Class IIa medical device, its own response to the UZ Gent study admits 83% sensitivity in a high-risk clinic population, and it is not sold in the US or Canada, so the feature people will pay most for ('tell me if this is dangerous') is exactly the one you cannot ship casually. Second, the plain tracking layer is crowded and cheap ('There are hundreds of them' per one opened HN comment). The wedge worth testing is the unglamorous, unregulated one: on-device photo baselines for every mole, a consistent re-shoot guide, side-by-side change review, and a printable dermatologist handoff, sold once rather than as a subscription, aimed at US high-risk users the incumbents do not serve. This is not a promise that it works. Before building, validate it: recruit 15 US adults who get annual skin checks or have a melanoma history, have each baseline five moles with two repeat photos over two weeks, then ask for a $19 one-time pre-order. Kill it if fewer than 5 pre-pay, or if more than half say a free app plus the phone camera and their dermatologist already does the job.